EU AstraZeneca Ruling — A Letdown For Life Sciences Cos.

Law360, New York (December 21, 2012, 1:13 PM EST) -- On Dec. 6, 2012, the EU Court of Justice dismissed AstraZeneca’s appeal of the General Court’s judgment in AstraZeneca PLC. v. Commission.[1] The Court of Justice affirmed the reasoning and holdings of the General Court and rejected all of AstraZeneca’s arguments, including its challenge to the General Court’s analysis of the definition of the relevant markets and the findings that AstraZeneca’s intellectual property and regulatory strategies related to its product Losec constituted an abuse of a dominant position in violation of Article 102 TFEU.

This judgment,...
To view the full article, register now.